Kaempferol Inhibits the Primary Attachment Phase of Biofilm Formation in Staphylococcus aureus
The ability to form biofilms on surfaces makes the main pathogenic factor in implanted medical device infections. The aim of this study was to discover a biofilm inhibitor distinct from the antibiotics used to prevent infections resulting from biofilms. Here, we describe kaempferol, a small molecule...
Saved in:
Published in | Frontiers in microbiology Vol. 8; p. 2263 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
15.11.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The ability to form biofilms on surfaces makes
the main pathogenic factor in implanted medical device infections. The aim of this study was to discover a biofilm inhibitor distinct from the antibiotics used to prevent infections resulting from
biofilms. Here, we describe kaempferol, a small molecule with anti-biofilm activity that specifically inhibited the formation of
biofilms. Crystal violet (CV) staining and fluorescence microscopy clearly showed that 64 μg/ml kaempferol inhibited biofilm formation by 80%. Meanwhile, the minimum inhibitory concentration (MIC) and growth curve results indicated that kaempferol had no antibacterial activity against the tested bacterial strain. Kaempferol inhibited the primary attachment phase of biofilm formation, as determined by a fibrinogen-binding assay. Moreover, a fluorescence resonance energy transfer (FRET) assay and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) analyses revealed that kaempferol reduced the activity of
sortaseA (SrtA) and the expression of adhesion-related genes. Based on these results, kaempferol provides a starting point for the development of novel anti-biofilm drugs, which may decrease the risk of bacterial drug resistance, to prevent
biofilm-related infections. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Emily E. Weinert, Emory University, United States; Fabian Davamani Amalraj, International Medical University, Malaysia; Sarah Rowe-Conlon, University of North Carolina at Chapel Hill, United States Edited by: Yuji Morita, Aichi Gakuin University, Japan These authors have contributed equally to this work. This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology |
ISSN: | 1664-302X 1664-302X |
DOI: | 10.3389/fmicb.2017.02263 |